<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396680</url>
  </required_header>
  <id_info>
    <org_study_id>TR006A</org_study_id>
    <nct_id>NCT02396680</nct_id>
  </id_info>
  <brief_title>Ragweed-SPIRE Follow-On Study</brief_title>
  <official_title>An Observational Follow-On Field Study to Evaluate the Continued Efficacy and Safety of Ragweed-SPIRE Treatment in Ragweed Allergic Subjects Approximately One Year After the Completion of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of Ragweed-SPIRE 12 months after the
      initial dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Approximately 12 months after first dose in TR006</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Score</measure>
    <time_frame>Approximately 12 months after first dose in TR006</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>Approximately 12 months after first dose in TR006</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Prick Test</measure>
    <time_frame>Approximately 12 months after first dose in TR006</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin E Test</measure>
    <time_frame>Approximately 12 months after first dose in TR006</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">249</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Ragweed Allergy</condition>
  <arm_group>
    <arm_group_label>TR006 Subjects</arm_group_label>
    <description>Subjects that have previously been randomised into study TR006</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who completed at least 6 of 8 treatment visits in Study TR006
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Â° Previously randomised into and completed at least 6 of 8 treatment visits in Study TR006

        Exclusion Criteria:

          -  Subject or Investigator have been informed of treatment received in Study TR006

          -  Subjects with significant allergy to animal dander

          -  Any allergen immunotherapy since completing Study TR006 or use of prohibited therapies

          -  History of recurrent acute sinusitis or chronic sinusitis

          -  Received treatment with an investigational drug within 4 weeks of Screening

          -  Unable to understand study requirements or unable to communicate clearly with
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kanata Allergy Services</name>
      <address>
        <city>Kanata</city>
        <state>Ontario</state>
        <zip>K2L 3C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inflamax Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Allergy Asthma Associates</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 2G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ragweed Allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Ragweed-SPIRE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

